Consolidated loss widens 148% YoY to ₹127.6 Cr as R&D spend surges on Phase 3 trials
PAT -147.66% YoY · revenue +90.98% · margins compressing
₹3.57 Cr
+90.98% YoY
₹-127.61 Cr
-147.66% YoY
-1150.74%
-1050.7pp YoY
₹-4.84
Consolidated net loss for the quarter ended 30 June 2026 (Q1 FY27) widened to ₹127.61 Cr, up 147.7% YoY from ₹51.52 Cr and 179.9% QoQ from ₹45.60 Cr, per un-audited results approved by the Board on 6 August 2026. Diluted EPS was -₹4.84 versus -₹2.36 a year ago. Revenue from operations was ₹3.57 Cr against ₹1.87 Cr YoY — traditional margin metrics (NPM/OPM) aren't meaningful here since Suven remains a pre-revenue, clinical-stage biopharmaceutical rather than a commercial-revenue business.
Q1 FY-2027 vs prior quarters
Consolidated R&D and operating expenses rose to ₹123.83 Cr from ₹41.49 Cr YoY (+198%) and ₹42.33 Cr QoQ (+193%), the direct driver of the wider loss; standalone R&D was a comparatively modest ₹12.76 Cr, confirming nearly all of the increase sits in the wholly-owned US subsidiary, Suven Neurosciences Inc. The auditor's limited-review report separately discloses the subsidiary posted a ₹111.49 Cr net loss (total comprehensive loss ₹111.47 Cr) on nil revenue for the quarter — consistent with the roughly ₹111.5 Cr gap between standalone (-₹16.12 Cr) and consolidated (-₹127.61 Cr) loss. There was no tax and no exceptional item in either the current or comparison periods, so no adjusted-vs-reported split is needed here.
The stock went into the print at ₹311, down 1.9% over the past month of trading.
For context: revenue is at a 6-quarter high.
Other income was ₹7.52 Cr, 68% of the ₹11.09 Cr total income, likely interest earned on the ₹857.64 Cr raised via convertible warrants, of which ₹448.14 Cr remained un-utilised as of 30 June 2026 (note 6). No management guidance or prior concall commentary is on record, and a web search turned up no brokerage previews or consensus estimates for this quarter — Suven carries no visible analyst coverage tracking its quarterly P&L, consistent with its status as a pre-commercial, trial-stage name; vs-street and vs-guidance are both unknown. Management's own news release does not address the loss at all, framing the quarter entirely around pipeline milestones instead.
W1
SUVN-502 Phase 3 full enrolment (targeted Sep 2026) and last-patient-last-visit in Q1 CY2027 — gates the Q2 CY2027 database lock/readout
W2
Consolidated R&D run-rate (₹123.83 Cr this quarter) as SUVN-G3031 ramps and SUVN-502 nears completion — sets the pace of cash burn
W3
Utilisation of the remaining ₹448.14 Cr of the ₹857.64 Cr warrant proceeds — determines next quarter's interest-income (other income) run-rate